Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, and Ferroptosis and cancer prognosis.
Cellular origins of mucinous ovarian carcinoma
Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Profiling the immune landscape in mucinous ovarian carcinoma
Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta‐analysis
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer
Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.
Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
Therapeutic options for mucinous ovarian carcinoma
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies new candidate susceptibility genes for breast and ovarian cancer
p53 immunohistochemistry is an accurate surrogate for <i>TP53</i> mutational analysis in endometrial carcinoma biopsies
The molecular origin and taxonomy of mucinous ovarian carcinoma
Oncogenic mutations in histologically normal endometrium: the new normal?